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Abstract
Rationale In Western societies, a considerable percentage
of young people expose themselves to 3,4-methylenedioxy-
methamphetamine (MDMA or “ecstasy”). Commonly,
ecstasy is used in combination with other substances, in
particular alcohol (ethanol). MDMA induces both arousing
as well as hallucinogenic effects, whereas ethanol is a
general central nervous system depressant.
Objective The aim of the present study is to assess the acute
effects of single and co-administration of MDMA and ethanol
onexecutive,memory,psychomotor,visuomotor,visuospatial
and attention function, as well as on subjective experience.
Materials and methods We performed a four-way, double-
blind, randomised, crossover, placebo-controlled study in
16 healthy volunteers (nine male, seven female) between
the ages of 18–29. MDMA was given orally (100 mg) and
blood alcohol concentration was maintained at 0.6‰ by an
ethanol infusion regime.
Results Co-administration of MDMA and ethanol was well
tolerated and did not show greater impairment of perfor-
mance compared to the single-drug conditions. Impaired
memory function was consistently observed after all drug
conditions, whereas impairment of psychomotor function
and attention was less consistent across drug conditions.
Conclusions Co-administration of MDMA and ethanol did
not exacerbate the effects of either drug alone. Although the
impairment of performance by all drug conditions was
relatively moderate, all induced significant impairment of
cognitive function.
Keywords MDMA.Ecstasy.Alcohol.Ethanol.
Interaction.Acute.Effects.Healthyvolunteers.
Neuropsychologic
Introduction
In Western societies, a considerable proportion of young
people expose themselves to 3,4-methylenedioxymetham-
phetamine (MDMA or ‘ecstasy’; Gross 2002; Parrott 2001;
Tancer and Johanson 2007). Ecstasy has gained widespread
use in the ‘club’ scene, typically all-night parties with loud
music and intense lights (Winstock et al. 2001). The
average dose of ecstasy used recreationally is reported to
be around 80–90 mg of MDMA with considerable
individual variation (Tanner-Smith 2006). Ecstasy users
are generally multidrug users who have experience with
various recreational drugs and use these in combination
with ecstasy (Gouzoulis-Mayfrank and Daumann 2006b).
Probably due to its availability, alcohol remains one of the
most co-used substances (Barrett et al. 2005). As the use of
alcohol is known to induce impairment of cognitive
function and decrease the awareness of this impairment,
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e-mail: G.J.H.Dumont@psy.umcn.nlthis can lead to dangerous behaviour like driving under
influence (Lamers and Ramaekers 2001; Riley et al. 2001).
MDMA acts primarily by releasing serotonin (5-
hydroxytryptamine (HT)) from pre-synaptic 5-HT termi-
nals. It reverses the direction of the reuptake transporter
and increases 5-HT levels at the post-synaptic receptors
(Liechti and Vollenweider 2000; Mlinar and Corradetti
2003; Pifl et al. 1995). MDMA is also a potent releaser of
dopamine and (nor)adrenaline (Colado et al. 2004; Liechti
and Vollenweider 2001).
MDMA is rapidly absorbed following oral administra-
tion. Within 30 min, MDMA is detectable in the blood.
Plasma levels peak at 1–2 h after drug administration, and
maximum behavioural and subjective effects occur around
1–2 h and have declined by 4 h in spite of persisting plasma
levels (de la Torre et al. 2004; Green et al. 2003). Increasing
the dose does not result in a proportional rise in plasma
concentrations, which is indicative of non-linear pharma-
cokinetics (de la Torre et al. 2000).
The behavioural effects of MDMA resemble but are not
restricted to effects of psychostimulants (e.g. amphetamines
or ‘speed’) as well as hallucinogenics (e.g. lysergic acid or
‘lysergic acid diethylamide’), although MDMA’sm o s t
characteristic effects are described as an increase in
empathy and friendliness (Vollenweider et al. 2002). This
led to MDMA being categorized as an ‘entactogen,’ as
coined by Nichols and Oberlender (1990).
Most research into the cognitive effects of MDMA in
humans has focused on the long-term effects, where only
memory was consistently found to be impaired (Verbaten
2003;V e r k e se ta l .2001). Our review of the acute effects
of MDMA in humans showed that cognitive effects were
assessed only in a limited number of studies, using diverse
tests and generally addressing only certain aspects of
neuropsychological function. As such, no consensus on
MDMA’s cognitive effects could be reached (Dumont and
Verkes 2006). Since then, reports on the effects of MDMA
generally confirmed previous findings (Kuypers et al.
2006;K u y p e r se ta l .2007; Ramaekers et al. 2006;T a n c e r
and Johanson 2007). Interestingly, two studies reported
effects of MDMA on memory, which had not been
assessed previously. These reports showed acute impair-
ment of immediate and delayed recall of words as well as
spatial memory by MDMA (Kuypers and Ramaekers
2005, 2007).
Drinks containing ethanol, commonly referred to as
alcohol, are widely available and regularly used in Western
society. Ethanol is chiefly a central nervous system (CNS)
depressant. It inhibits both excitatory and inhibitory post-
synaptic potentials by potentiating the action of gamma-
aminobutyric acid at its receptor (Suzdak et al. 1988).
Reports of the cognitive effects of combined use of MDMA
and ethanol in humans have been sparse in the literature.
Studies that were performed assessed psychomotor function,
attentional performance and subjective effects (Hernandez-
Lopez et al. 2002; Kuypers et al. 2006; Ramaekers et al.
2006). In general, MDMA and ethanol had no or opposite
effects on effect measures, and as such co-administration
did not exacerbate single-drug effects.
In the current study, we employed a series of tests
sensitive to changes in all common neuropsychological
domains induced by several pharmacological compounds,
including amphetamines (Wezenberg et al. 2004).
It is generally acknowledged that the combined use of
alcohol with other CNS-depressant drugs may enhance the
effects of ethanol or of the other drugs. MDMA, however,
has stimulant effects while ethanol is a sedative agent,
suggesting that the effects of co-administration are dimin-
ished rather than augmented compared to the effects
following single administration. This hypothesis was
investigated during acute co-administration of MDMA
and ethanol in healthy volunteers.
Materials and methods
Study design
This study utilised a four-way, double-blind, randomised,
crossover, placebo-controlled design. Sixteen volunteers
were randomly assigned to one of four treatment sequences.
Each volunteer received a capsule containing either 100-mg
MDMA or placebo and an ethanol–placebo infusion (target
blood alcohol concentration (BAC) of 0.6‰) with a
washout of 7 days between each treatment.
Study outline
Subjects arrived in the morning and were admitted to the
study after a negative urine drug screen (opiates, cocaine,
benzodiazepines, amphetamines, methamphetamines and
delta-9-tetrahydrocannabinol), as well as a negative alcohol
breath test and recording of signs and symptoms of possible
health problems. A light breakfast was offered. Drug
administration was scheduled at 1030 hours and the alcohol
infusion was started at 1100 hours for a duration of 3 h. At
1130 hours, subjects performed the psychological test
battery as described below. Specific test times are reported
in Table 1. Subjects received lunch at 1400 hours and were
sent home at 1700 hours after a medical check. Adverse
events where recorded throughout the study day. Vital signs
were monitored using a Datascope® Accutorr Plus™
cardiovascular monitor and Braun® type 6021 ThermoScan
during the study day. The data presented in this report are a
subset of a larger data set, which will be reported
elsewhere.
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Sixteen healthy volunteers (nine male, seven female),
regular users of ecstasy and alcohol, aged 18–29 years
a n dw i t h i n8 0 –130% of their ideal bodyweight, were
recruited through advertisement on the internet and at local
drug testing services. They were all in good physical and
mental health as determined by assessment of medical
history, a medical, electrocardiogramme and clinical,
haematological and chemical blood examination. Previous
drug use was assessed using a structured interview. Fifteen
volunteers were right handed and one was left handed. The
study was approved by the local Medical Ethics Commit-
tee. All subjects gave their written informed consent before
participating in the study and were compensated for their
participation. Subject demographics and drug history are
reported in Table 2.
One subject had a mild adverse reaction (local vascular
reaction) to the alcohol infusion and one subject did not
refrain from drug use; both (one male, one female) were
excluded from further participation and results obtained
were not included in the data analysis.
Drugs and dosages
MDMA (or matched placebo) was given as a capsule in a
single dose of 100 mg via oral administration (dose range;
1.1–2.2 mg/kg). MDMA was obtained from Lipomed AG,
Arlesheim, Switzerland and encapsuled according to Good
Manufacturing Practise by the Department of Clinical
Pharmacy, UMC St Radboud, Nijmegen, the Netherlands.
MDMA 100 mg orally is a relevant dose in the range of
normal single recreational dosages. Previous experiments in
humans used doses up to 150 mg without serious adverse
events. Ethanol (or matched placebo) was administered
continuously by intravenous infusion of 10% ethanol in
glucose solution resulting in an ethanol blood concentration
of 0.6‰ with a duration of 3 h as described below.
Alcohol clamping
To standardise alcohol delivery and maintain a constant
alcohol blood concentration over time, an intravenous
ethanol clamp was used. Ethanol was administered by
infusion of a 10% ethanol in glucose solution for a duration
of 3 h. The infusion rate was calculated using frequent
breath alcohol concentrations measurements, according to a
previously designed algorithm (Amatsaleh et al. 2006a).
Breath alcohol concentration was assessed using a HONAC
AlcoSensor IV® Intoximetre.
An intravenous administration route was chosen,
ensuring standardisation of the rate and bioequivalence
of ethanol administration. This is an important pre-
requisite for predictable pharmacokinetics of ethanol.
The process was semi-automated using a computer
Table 2 Volunteer demographics–drug history
Mean SD Min Max
Age (years) 22.1 2.9 18.0 29.0
Education (years) 16.5 1.6 12 18
Height (cm) 174.7 12.3 147.0 189.1
Weight (kg) 67.5 12.4 45.7 88.4
Opiates 0.1 0.3 0 1
LSD 2.5 6.6 0 25
Amphetamines 37.3 81.1 0 250
Ecstasy 94.6 138.4 14 431
Cannabis 1,174.3 1,665.5 20 5,840
Cocaine 33.7 105.7 0 400
Alcohol 2,367.9 1,981.6 50 5,200
Solvents 3.6 13.3 0 50
Barbiturates 0 0 0 0
Benzodiazepines 18.6 57.3 0 216
Psilocybin 6.9 10.4 0 30
Drug quantities mentioned are lifetime drug exposures, not further
specified.
Table 1 Timeline
Neuropsychological tests Description Time (h:m)
Drug administration 0:00
18-word list immediate recall Immediate recall of 18-word list 1:00
SDST Translate symbols to digits with key present in 90 s 1:05
SDRT Translate symbols to digits from memory 1:08
Pursuit task Keep dot within moving circle 1:10
Tangles task Tangled line leads to which target? 1:13
Switch task Follow, possibly conflicting, instructions (choice between left or right) 1:17
18-word list delayed recall Delayed recall of 18-word list 1:22
18-word list delayed recognition Recognise words of 18-word list memorised earlier among 18 distracters 1:23
Point task Keep pen steady in air, measures tremor 1:25
Visual analogue scales 16 100-mm scales for subjective experiences 1:30
Times are relative to drug administration.
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alcohol concentrations to calculate the infusion rate
needed to maintain the ethanol level at 0.6 mg/mL. This
is a relevant dose equivalent to peak levels of approx-
imately two to three units of alcoholic beverages. In
many European countries driving is prohibited at BAC
above 0.5‰. This limit has been confirmed by a report
t h a ts h o w st h a ta ta na v e r a g eB A Co f0 . 6 ‰ psychomotor
performance is significantly impaired (Amatsaleh et al.
2006b). A BAC of 0.6‰ is equivalent to approximately
two to three alcoholic beverages commonly used in social
settings in Western society, which is considered to be a
safe and relatively moderate dose, despite its significant
CNS effects.
MDMA blood analysis
For the assessment of serum levels of MDMA, blood
samples were collected 90 min after drug administration
from each subject on each study day. Venous blood samples
(10 ml) were collected into heparinised tubes, centrifuged
immediately at 4°C for 15 min. Plasma was split into
aliquots of 2 mL (to prevent over-freezing–thawing), frozen
rapidly using liquid nitrogen and stored at −80°C. Samples
were analysed for MDMA and MDA concentration by the
Toxicology unit of the Leyenburg hospital, The Hague, the
Netherlands.
Neuropsychological tests, apparatus and procedure
The performance on all neuropsychological tests was
recorded by means of a digitising tablet (WACOM UD-
1218-RE), a laptop computer, a pressure-sensitive pen
(which could also be used as a cursor) and test forms.
The x and y coordinates of the pen tip on and up to 5 mm
above the digitiser were sampled with a frequency of
200 Hz and a spatial accuracy of 0.2 mm. The time
schedule of the tests is summarised in Table 1.
To familiarise the subjects with the tests and procedures,
they were invited to the hospital to perform a practise
session within 1 week before the actual study days. All tests
had five equivalent versions for four test days and one
practise day, test versions were counterbalanced over test
days.
Executive function
Switch task This test is a reaction time task measuring
simple as well as complex reaction time, assessing
executive performance (Baker and Letz 1986). After a
random period of 0.75 to 1.75 s, two rectangular fields
appeared on both sides of a circle in the centre of the
screen. Only one of the two fields provided the subjects
with information, either a colour, an arrow or both. The
other non-informative field always had a neutral grey
colour. Five conditions were subsequently presented to
subjects. If only green fields appeared, subjects had to
move as fast as possible into the green field. If green and
red fields appeared, subjects had to move into the green
field and away from the red field as soon as they
appeared.
If green fields with a left or right arrow were presented,
subjects were to move into the direction of the arrow. Green
and red fields with a left or right arrow indicated that
subjects were to follow the direction of the arrows in the
green field, but the opposite direction of the arrows in the
red field. Finally, the first condition was repeated. All
conditions contained 20 trials except condition four in
which there were 40 trials (total=120 trials). The outcome
measures were the mean reaction times per condition. The
last condition is a repetition of the first to check for possible
changes in attention.
Memory
Eighteen-word list A verbal memory test based on the
classic Auditory Verbal Learning Test (Vakil and Blachstein
1993) was used. A variant was made consisting of a list of
18 words. The classic test uses 15 words. A longer wordlist
was chosen, however, to prevent ceiling effects. The list
was presented verbally three times. Under normal circum-
stances, subjects are supposed to remember an increasing
number of words after each trial. Directly after each
presentation, and after an interval of 20 min, subjects were
asked to recall as many words as possible. After the delayed
recall trial, a list of 36 words was presented from which
they were asked to recognise the 18 words previously
presented. The incorrect words were distracters and
resembled the correct words in a semantic or phonologic
manner. Responses were either correct positive (when a
word that was recognised was indeed part of the list
presented during immediate recall) or false positive (when a
word was recognised but was not part of the list presented
during immediate recall, e.g. the word was a distracter).
The outcome measure was the number of correctly recalled
or recognised words for the average of the three immediate
recall trials, the delayed recall trial and the delayed
recognition trial.
Symbol digit recall test The symbol digit recall test
(SDRT) followed directly after the Symbol Digit Substi-
tution test (SDST), which is discussed in the last
paragraph of this section. After subjects had finished
the SDST, they were shown the symbols of the SDST
468 Psychopharmacology (2008) 197:465–474without the translation key, one at a time, and asked to
produce the corresponding numbers. This test is based on
an extended procedure of the SDST to measure inciden-
tal learning (Kaplan et al. 1991). The outcome measure
was the number of correctly translated symbols.
Psychomotor function
Pursuit task To measure implicit procedural learning, a
computerised version of the rotor pursuit task was used.
This test is based on the classic rotary pursuit task
(Ammons 1951). It is a continuous motor task. Subjects
had to follow the movement of a large target stimulus on
the computer screen with a cursor by moving the pen over
the XY tablet. The speed of the target gradually increased
when the cursor was contained within the target but
decreased considerably when it was not. The target
followed a spatially predictable circular path over the
screen. The outcome measure for this test was the total
number of rotations within 2 min.
Point task The point task, a measure for tremor, required
subjects to try to keep the cursor inside a very small circle
for 1 min, while avoiding contact between the pen and the
test form. The outcome measure for this test was the
deviation from the target.
Visuospatial and visuomotor function
Tangle task The tangle task required the subject to
visually track a particular line winding through two to
four other lines. On subsequent trials, the tangles
increased in complexity; they got longer and made more
90° turns. The paper form had a start area and five target
areas, numbered 1 to 5, which reflect the maximum
target areas on the screen, starting with only three target
areas.
This test is modelled after the visualisation test from
the ‘kit for factor referenced cognitive tests.’ It was
selected by the US NAVY to study environmental and
other time-course effects and has good task stability and
reliability (Bittner et al. 1986). The outcome measures
are the reaction time per trial and the number of correct trials
in 2 min.
Attention
Symbol Digit Substitution test This test is a version of the
subtest from the Wechsler Adult Intelligence Scale
(Wechsler 1981). Subjects had to substitute the nine
symbols for the digits 1–9 on the basis of a given
translation key. The outcome measure was the total
number of digits completed in 90 s.
According to Hege et al. (1997)t h i st a s km e a s u r e s
many cognitive components, e.g. visuospatial scanning,
intermediate memory, perceptual motor speed and speed
of cognitive processing. Therefore, subsequent analyses
were performed in order to attempt and disentangle these
cognitive processes. Based on pen pressure, movement
trajectories were defined as either pen-up periods or pen-
down periods. This allowed for subsequent analysis of
matching times and movement (writing) times in the
Symbol Digit Substitution test. For the motor component,
the mean writing times were computed. For the more
cognitive component, the mean matching times were
computed. These analyses have been previously per-
formed (Sabbe et al. 1999; Wezenberg et al. 2005).
Subjective
Subjective effects were recorded using the Bond and
Lader (Visual Analogue) Mood Rating Scale (BLMRS).
This inventory was completed at the end of each
neuropsychological test battery on each study day.
The BLMRS scale consisted of 16 lines, each 10 cm
in length, with opposite terms at each end of the line
(alert–drowsy, calm–excited, strong–feeble, muzzy–clear-
headed, well coordinated–clumsy, lethargic–energetic,
contented–discontented, troubled–tranquil, mentally
slow–quick witted, tense–relaxed, attentive–dreamy,
incompetent–proficient, happy–sad, antagonistic–amicable,
interested–bored, withdrawn–gregarious). Subjects were
asked to indicate which item was more appropriate by
marking the line. The outcome measure was the distance to
the marker on each scale. These scale scores were then
aggregated to scores for ‘calmness,’‘ alertness’ and ‘con-
tentedness’ as described by Bond et al. (1974).
Statistical analyses
Statistical evaluation (using SPSS 11.5 for Windows)
was performed with general linear model repeated-
measures analysis of variance. Main and interaction
effects were tested using a two-factor (‘ethanol’ and
‘MDMA’), two-level (absent versus present) multivariate
model.
The analysis of the data was based on Maxwell and
Delaney (2004) and Kirk (1995). First the presence of
interaction (non-additivity) was tested with alfa=0.05.
When the interaction was not statistically significant we
proceeded by testing the main effects, each at alfa=0.05. In
the case of a significant interaction, we proceeded by
Psychopharmacology (2008) 197:465–474 469testing simple main effects of each drug, i.e. MDMA vs.
placebo and ethanol vs. placebo.
Results
Subject demographics are summarised in Table 2.O u to f
16 subjects, 14 completed the study procedure. One
subject had a mild adverse reaction (local vascular
reaction which subsided with infusion stop) to the alcohol
infusion and one subject did not refrain from drug use;
both were discontinued from study participance and data
already obtained were not included in statistical analysis.
Only significant results are mentioned in this section,
unless stated otherwise.
MDMA blood concentration 90 min after administration
did not differ for MDMA single vs. MDMA and ethanol
co-administration and was on average 196 μg/L (SD=
83 μg/L). Blood alcohol concentration was maintained at
an average of 0.54‰ (SD=0.07‰).
Executive function
Executive function (switch task) did not show any
significant main or interaction effects.
Memory function
Memory function was assessed by the 18-word list
(outcome measures were ‘immediate recall,’‘ delayed
recall’ and ‘recognition,’ see Fig. 1) as well as the SDRT.
Immediate recall was impaired only by ethanol (F(1, 12)=
8.71, p=0.011).
Delayed recall as assessed by the 18-word list was
impaired by MDMA (F(1, 12)=10.447, p=0.007) as well
as by ethanol (F(1, 12)=16.031, p=0.002). The SDRT, also
a test for delayed recall, showed a similar pattern of
impairment by MDMA (F(1, 12)=5.300, p=0.038) as well
as by ethanol (F(1, 12)=7.654, p=0.016).
Psychomotor function
Psychomotor function was assessed with tests for tremor
(point task), accuracy (pursuit task) and speed (SDST motor
time, see Fig. 2); other SDST results are reported in the
section “Attention.” Ethanol impaired psychomotor speed
as reflected in the increase in SDST motor time (F(1, 12)=
9.295, p=0.009).
Visuospatial and visuomotor function
Visuospatial and visuomotor function were measured with
the tangle task, subdivided into ‘total number correctly
solved’ and ‘reaction time,’ and did not show any
significant effects, although a trend of impairment by
MDMA (F(1, 12)=3.966, p=0.068) was observed.
Attention
Attention was assessed with the SDST task; the outcome
measures were ‘motor time’ (see “Psychomotor function”),
‘matching time’ (Fig. 3)a n d‘total number correctly
substituted.’ T h et i m er e q u i r e dt om a t c hs y m b o l st ot h e
corresponding numbers showed a significant MDMA and
ethanol interaction (F(1, 12)=6.214, p=0.027). Tests for
simple main effects revealed that both single-drug con-
ditions reduced attention compared to placebo (ethanol
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Fig. 1 Memory effects (18-word list), Immediate: immediate recall,
average score of three trials of correctly recalled verbally presented
words, Delayed: correctly recalled verbally presented words 20 min
after presentation, Recognition: correctly recognised verbally pre-
sented words containing 18 distracters, 20 min after presentation
(mean and SEM). Immediate recall was impaired only by ethanol
(F(1, 12)=8.71, p=0.011). Delayed recall was impaired by MDMA
(F(1, 12)=10.447, p=0.007) as well as by ethanol (F(1, 12)=16.031,
p=0.002); recognition was not affected by any drug condition
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Fig. 2 Psychomotor effects: SDST writing time (mean, SEM).
Ethanol increased writing times (F(1, 12)=9.295, p=0.009)
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0.022; see Fig. 3).
Subjective effects
Subjective effects are depicted in Fig. 4. Feelings of
‘contentedness’ where increased significantly by MDMA
only (F(1, 12)=4.710, p=0.049).
A significant interaction effect (F(1, 12)=7.358, p=
0.018) was found for feelings of ‘alertness.’ Tests for
simple main effects revealed that ethanol but not MDMA
significantly decreased feelings of alertness compared to
placebo (F(1, 13)=50.613, p<0.001). Feelings of ‘calm-
ness’ were reduced only by MDMA (F(1, 12)=20.259,
p=0.001).
Discussion
This study demonstrates that the effects of 100-mg MDMA,
commonly known as ecstasy, on cognitive function are no
greater than the effects of a relatively low dose of ethanol.
This is remarkable as these results suggest that the effects
of 100-mg MDMA are comparable to the peak effects of
two to three alcoholic beverages. Co-administration of
these compounds did not result in any significant cognitive
impairments beyond those observed after administration of
only ethanol. The use of moderate amounts of alcohol is
common in Western societies and, although impairing
cognitive function, socially accepted, while ecstasy use
remains very controversial. Of course, our findings only
relate to the acute neuropsychological implications of
ecstasy use and not to the physiological and long-term
effects, which rightfully remain topics of discussion
(Gouzoulis-Mayfrank and Daumann 2006a; Nutt 2006;
Parrott 2007).
Drug effects observed in this placebo-controlled cross-
over study were moderate. Co-administration was well
tolerated as indicated by the subjective scores, which were
comparable to those found after single administration of
MDMA. An interaction of MDMA and ethanol was found
for subjective alertness scores. Ethanol, as expected,
reduced subjective alertness, while MDMA co-administration
reversed the reduction of subjective alertness by ethanol. In
the present study, MDMA by itself did not significantly
affect subjective alertness, although this effect has been
consistently reported in other studies and is a well-known
effect of amphetamines. However, MDMA did significantly
reduce subjective calmness, i.e. subjects felt more excited
after MDMA use. Probably, the Bond and Lader Mood
Rating Scale is not well suited for the assessment of
subjective effects of psychoactive drug effects and future
studies should employ more appropriate subjective drug
effect measures such as the Profile Of Mood States (de Wit
et al. 2002).
When considering the results for each neuropsycholog-
ical domain, executive function was not affected by any
drug condition. A previous study showed impairment of
executive function by ethanol but not MDMA, although
ethanol impaired performance in only one out of three tests
of executive function (Lamers et al. 2003). The BAC in this
study was 0.3‰ at the time of testing compared to 0.56‰
in our current study, suggesting a lack of sensitivity of the
test employed in the current study.
The above-mentioned previous study also reported
visuospatial and visuomotor impairment by MDMA but
not by ethanol. Although not significant, our current results
show a similar pattern where MDMA showed a trend of
impairment of visuospatial and visuomotor function,
whereas ethanol did not.
900
950
1000
1050
1100
1150
1200
1250
M
a
t
c
h
i
n
g
 
t
i
m
e
 
(
m
s
)
placebo ethanol MDMA MDMA+ethanol
Fig. 3 Attention effects: SDST matching time, i.e. time needed for
translation (mean and SEM). A significant MDMA by ethanol
interaction was found (F(1, 12)=6.214, p=0.027)
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Fig. 4 Subjective effects (aggregated Bond and Lader scores, mean
and SEM). Feelings of ‘Contentedness’ where increased signifi-
cantly by MDMA only (F(1, 12)=4.710, p=0.049) A significant
interaction effect (F(1, 12)=7.358, p=0.018) was found for feelings
of ‘Alertness.’ Feelings of ‘Calmness’ were reduced only by MDMA
(F(1, 12)=20.259, p=0.001)
Psychopharmacology (2008) 197:465–474 471Psychomotor function was impaired only after ethanol
administration (SDST motor time, see Fig. 2). The majority
of studies addressed in our review of acute effects of
MDMA in humans (Dumont and Verkes 2006) did not
report any change in psychomotor function after MDMA
either. However, increased psychomotor function after
MDMA has also been found (Lamers et al. 2003;
Ramaekers et al. 2006). These studies administered 75 mg
instead of 100 mg. Possibly, the effects of MDMA are
biphasic, with a low dose of MDMA exhibiting more
amphetamine-like effects, e.g. arousal, increasing perfor-
mance, whereas higher doses may elicit more hallucino-
genic effects and impair performance (Liechti et al. 2001;
Solowij et al. 1992).
As mentioned above, MDMA co-administration re-
versed the ethanol-induced feelings of sedation, although
MDMA was unable to reverse the psychomotor impair-
ment induced by ethanol. This dissociation between
subjective and objective sedation confirms previous find-
ings by Hernandez-Lopez et al. (2002).
Several studies assessed MDMA’s effect on attention
using the Digit Symbol Substitution Task (DSST), although
no significant effects were found (Cami et al. 2000; Farre et
al. 2004; Kuypers and Ramaekers 2005). One study
reported decreased DSST performance after ethanol as well
as after ethanol and MDMA co-administration but no effect
of MDMA (Hernandez-Lopez et al. 2002). Our findings
confirm these findings to a large extent. We found no main
effects of MDMA or ethanol on attention, although an
interaction of ethanol and MDMA for ‘matching time’
(time required to match the number to the corresponding
symbol) was found. Co-administration of MDMA and
ethanol increased ‘matching time’ comparable to the
increase observed after both MDMA and ethanol single
administration, compliant with our hypothesis of competi-
tive mechanisms of action of both drugs (see Fig. 3).
Studies investigating the long-term effects of MDMA
consistently found memory to be affected (Verbaten 2003).
In the present report, almost all memory measures showed
quantitatively comparable impairment for each drug condi-
tion (see Fig. 1), although the effect of MDMA on
immediate recall did not reach statistical significance. Only
delayed recognition was not impaired in any drug condi-
tion. These findings suggest a deficit in the retrieval of
verbal information encoded in memory, rather than impair-
ment in the storage of information. Our findings are similar
to the results of a previous study on MDMA-induced
effects on memory (Kuypers and Ramaekers 2005). In this
previous study, no memory impairment was observed after
methylphenidate administration, a pronounced dopamine
and norepinephrine releaser, suggesting the involvement of
serotonin in memory impairment. Several other studies also
have shown serotonin-mediated modulation of memory
function through interaction with the cholinergic neuro-
transmitter system, although the details of this complicated
interaction remain elusive (Cassel and Jeltsch 1995; Garcia-
Alloza et al. 2006; Meneses 2007). Generally, subjects
stated that they were well aware of their impaired memory
after MDMA.
BAC was on average 0.56‰. At this level, driving is
prohibited by law in many European countries because of
its interference with normal functioning. Although the
effects were moderate, ethanol impaired cognitive perfor-
mance in various tests. Similar moderate effects were
observed with MDMA 100 mg, considered to be slightly
above the average recreational dose (Tanner-Smith 2006).
This might be considered surprising for a drug with
reported robust subjective stimulating and hallucinogenic
properties. However, because the effects caused by a single
dose of 100-mg MDMAwere comparable to the effects of a
BAC of 0.56‰, this dose should by inference be
considered unacceptable in motorised traffic.
Arguably, the moderate drug effects as found in this
study could be explained by ‘missing’ the time of the
maximal drug effects. Although the average MDMA blood
concentration reported here (196μg/L) is comparable to
Cmax of 100-mg MDMA (199.8μg/L) as reported by de la
Torre et al. (2000), MDMA concentration was assessed at
the end of the testing procedure. However, Hernandez-
Lopez et al. (2002) found significant effects at 60 min as
well as 90 min after drug administration, arguing against
the suggestion of ‘missing’ peak drug effects.
The circumstances in which these substances are
normally used cannot be fully recreated in the laboratory
and this may have suppressed the effects of both sub-
stances. It is not unlikely that these substances show
enhanced effects when tested under typical circumstances
and surroundings. Recently, Parrott et al. (2006) concluded
that the increase in physical activity and body temperature
typically experienced when using MDMA enhance MDMA
effects. Ball et al. (2006) demonstrated that a familiar
surrounding increased MDMA-induced locomotor response
as well as single-neuron activity in rats, compared to
unfamiliar surroundings. Therefore, the psychosocial con-
text in which MDMA is used, along with the different
expectations and behaviour, probably influences its effects
(Sumnall et al. 2006). It is unlikely, however, that this
affects the quality of the interactions of MDMA and
ethanol.
In conclusion, co-administration of MDMA and ethanol
did not impair cognitive function significantly more than
MDMA or ethanol administration alone. The most prom-
inent effect of (co-)administration of MDMA and ethanol
was an impairment of memory. Ethanol also impaired
psychomotor function. Although the impairment of perfor-
mance by each drug condition was relatively moderate, this
472 Psychopharmacology (2008) 197:465–474significant impairment of cognitive function should be
considered intolerable in motorised traffic and other
cognitively demanding situations as confirmed by previous
research and as defined by law. However, the effects of
these drugs in the concentrations used in the present study
on established neuropsychological tests appear to be
smaller than one would assume based on their reputation.
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